Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas J Short

Showing results (261-270 of 346) with videos related to

Pageof 35
Sort By:
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 15, 2021
Myeloid/lymphoid neoplasms with FLT3 rearrangementGuilin Tang, Wayne Tam, Nicholas J Short, et al.
Blood|August 5, 2017
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPNElias Jabbour, Nicholas J Short, Guillermo Montalban-Bravo, et al.
British Journal of Haematology|October 10, 2025
CD123 expression and its correlation with mutation profile in acute myeloid leukaemiaRoberta S Azevedo, Sa A Wang, David M Swanson, et al.
The Lancet. Oncology|January 21, 2018
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 studyHagop Kantarjian, Farhad Ravandi, Nicholas J Short, et al.
Haematologica|May 2, 2024
Outcomes and genetic dynamics of acute myeloid leukemia at first relapseAlex Bataller, Hagop Kantarjian, Alexandre Bazinet, et al.
Cancer|July 15, 2017
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemiaElias Jabbour, Nicholas J Short, Farhad Ravandi, et al.
Cancer|September 8, 2016
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemiaElias Jabbour, Nicholas J Short, Jeffrey L Jorgensen, et al.
American Journal of Hematology|September 2, 2022
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remissionNicholas J Short, Walid Macaron, Tapan Kadia, et al.
Blood Advances|January 11, 2024
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemiaNicholas J Short, Elias Jabbour, Nitin Jain, et al.
Journal of Hematology & Oncology|June 27, 2026
Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II studyNicholas J Short, Alex Bataller, Courtney D DiNardo, et al.
Pageof 35

Showing results (261-270 of 346) with videos related to

Sort By:
Pageof 35
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 15, 2021
Myeloid/lymphoid neoplasms with FLT3 rearrangementGuilin Tang, Wayne Tam, Nicholas J Short, et al.
Blood|August 5, 2017
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPNElias Jabbour, Nicholas J Short, Guillermo Montalban-Bravo, et al.
British Journal of Haematology|October 10, 2025
CD123 expression and its correlation with mutation profile in acute myeloid leukaemiaRoberta S Azevedo, Sa A Wang, David M Swanson, et al.
The Lancet. Oncology|January 21, 2018
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 studyHagop Kantarjian, Farhad Ravandi, Nicholas J Short, et al.
Haematologica|May 2, 2024
Outcomes and genetic dynamics of acute myeloid leukemia at first relapseAlex Bataller, Hagop Kantarjian, Alexandre Bazinet, et al.
Cancer|July 15, 2017
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemiaElias Jabbour, Nicholas J Short, Farhad Ravandi, et al.
Cancer|September 8, 2016
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemiaElias Jabbour, Nicholas J Short, Jeffrey L Jorgensen, et al.
American Journal of Hematology|September 2, 2022
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remissionNicholas J Short, Walid Macaron, Tapan Kadia, et al.
Blood Advances|January 11, 2024
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemiaNicholas J Short, Elias Jabbour, Nitin Jain, et al.
Journal of Hematology & Oncology|June 27, 2026
Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II studyNicholas J Short, Alex Bataller, Courtney D DiNardo, et al.
Pageof 35